Inovio Pharma reports positive interim data from Phase 2 glioblastoma trial

Inovio Pharmaceuticals (NASDAQ:INO) reported positive interim results from its Phase 2 study of INO-5401 for the treatment of newly-diagnosed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

INO-5401 is a T cell-activating immunotherapy that encodes for three tumor-associated antigens. The 52-patient trial is assessing INO-5401 in combination with INO-9012, an immune activator encoding IL-12, and Regeneron Pharmaceuticals’ (NASDAQ:REGN) Libtayo, a PD-1 blocking antibody. 

Key interim data demonstrated that 80% of MGMT gene promoter methylated patients and 75% of unmethylated patients were progression-free at six months. The company plans to report additional data, including 12- and 18-month overall survival, in 2020.

“Our new data demonstrates the potential of our immunotherapies utilizing tumor-associated antigens in cancer treatments,” Dr. Joseph Kim, Inovio’s president and CEO, said in a statement. 

“Our goal in this GBM trial is to increase progression-free and overall survival of patients facing a disease where neither the standard of care nor clinical outcomes have significantly advanced in decades,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.